Journal article icon

Journal article

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.

Abstract:

Although the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known about the safety of HLA-mismatched DLI for the treatment of relapse. We examined the outcome of 58 consecutive leukaemia patients who received escalating-dose DLI for treatment of relapse after alemtuzumab-conditioned myeloablative unrelated donor HSCT at our institution. High-resolution HLA typing on stored DNA samples revealed mismatche...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1038/bmt.2013.69

Authors


Beattie, R More by this author
Sergeant, R More by this author
Expand authors...
National Institute for Health Research More from this funder
Publisher:
Nature Publishing Group Publisher's website
Journal:
Bone Marrow Transplantation Journal website
Volume:
48
Issue:
10
Pages:
1324-1328
Publication date:
2013-10-05
DOI:
EISSN:
1476-5365
ISSN:
0268-3369
URN:
uuid:330b7896-d9ff-43cc-af32-d236d9c964a0
Source identifiers:
508067
Local pid:
pubs:508067

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP